Atrial Flutter
📧 Sign up to get email alerts when something new happens for Atrial Flutter.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2011-03-11FDA Approved: MULTAQ — Supplemental Application (Sanofi-Aventis U.S. LLC)
The FDA approved the supplemental application for Multaq (dronedarone) filed by Sanofi-Aventis U.S. LLC.
-
CLINICAL_TRIALS trial_result · 2011-02-24Clinical Trial Update: Safety and Efficacy of the CryoCor™ Cardiac Cryoablation System for the Treatment of Atrial Flutter [Phase 3]
A Phase 3 clinical trial evaluating the CryoCor Cardiac Cryoablation System for atrial flutter has completed, with safety and efficacy data …
-
FDA approval · 2011-02-11FDA Approved: MULTAQ — Supplemental Application (Sanofi-Aventis U.S. LLC)
The FDA approved a supplemental application for MULTAQ (dronedarone) submitted by Sanofi-Aventis U.S. LLC.
-
FDA approval · 2011-01-27FDA Approved: DILTIAZEM HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for Diltiazem Hydrochloride from Teva Pharmaceuticals USA, Inc., updating the product's regulato…
-
FDA approval · 2011-01-20FDA Approved: DILTIAZEM HYDROCHLORIDE — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for diltiazem hydrochloride (Apotex Corp.), a generic calcium channel blocker. The approval covers t…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2010-11-23FDA Approved: CARDIZEM LA — Supplemental Application (Bausch Health US LLC)
FDA's entry shows a supplemental application submission for Cardizem LA (diltiazem hydrochloride extended-release). The sponsor is Bausch He…
-
FDA approval · 2010-11-22FDA Approved: CARDIZEM CD — Supplemental Application (Bausch Health US LLC)
The FDA approved a supplemental NDA for Cardizem CD (diltiazem hydrochloride) submitted by Bausch Health US LLC.
-
FDA approval · 2010-10-18FDA Approved: PROPAFENONE HYDROCHLORIDE — Supplemental Application (Strides Pharma Science Limited)
FDA approves a supplemental application for Propafenone hydrochloride from Strides Pharma Science Limited to market its generic product.
-
FDA approval · 2010-10-18FDA Approved: PROPAFENONE HYDROCHLORIDE — Original Application (Strides Pharma Science Limited)
FDA approved Propafenone hydrochloride from Strides Pharma Science Limited under an Original Application, making a generic antiarrhythmic av…
-
FDA approval · 2010-08-31FDA Approved: AMIODARONE HYDROCHLORIDE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for amiodarone hydrochloride from Zydus Lifesciences Limited, authorizing the continued marketing of…
-
FDA approval · 2010-08-12FDA Approved: VERAPAMIL HYDROCHLORIDE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for verapamil hydrochloride from Mylan Pharmaceuticals Inc., granting/confirming approval for a …
-
FDA approval · 2010-07-06FDA Approved: DIGOXIN — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for Digoxin from Sun Pharmaceutical Industries, expanding/ updating the approved Digoxin product…
-
FDA approval · 2010-05-18FDA Approved: DIGOXIN — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for Digoxin (Sandoz Inc), indicating an approved modification to this generic product's labeling/app…
-
CLINICAL_TRIALS research · 2010-04-30Clinical Trial Update: Tricuspid Isthmus Imaged by CARTOsound, Patients With Typical Atrial Flutter
The document provides an update on a clinical trial using CARTOsound to image the tricuspid isthmus in patients with typical atrial flutter.
-
FDA approval · 2010-04-26FDA Approved: DIGOXIN — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
FDA approves Amneal Pharmaceuticals of New York LLC's supplemental application for Digoxin (DIGOXIN), a generic product.
-
FDA approval · 2010-03-15FDA Approved: MATZIM LA — Original Application (Actavis Pharma, Inc.)
FDA approved MATZIM LA, a diltiazem hydrochloride extended-release tablet, under Actavis Pharma's original ANDA.
-
CLINICAL_TRIALS trial_result · 2010-03-02Clinical Trial Update: Catheter Evaluation for Endocardial Ablation in Patients With Typical Atrial Flutter [Phase 4]
A Phase 4 trial evaluating an endocardial ablation catheter for typical atrial flutter has completed, with results posted in 2010.
-
CLINICAL_TRIALS trial_result · 2010-02-15Clinical Trial Update: American-Australian-African Trial With Dronedarone in Patients With Atrial Fibrillation or Atrial Flutter for the Maintenance of Sinus Rhythm [Phase 3]
A Phase 3 trial evaluating dronedarone for maintaining sinus rhythm in patients with atrial fibrillation or atrial flutter has completed.
-
CLINICAL_TRIALS trial_result · 2010-02-09Clinical Trial Update: EURopean Trial In Atrial Fibrillation(AF) or Flutter (AFL) Patients Receiving Dronedarone for the maIntenance of Sinus Rhythm (EURIDIS) [Phase 3]
Phase 3 EURIDIS trial evaluating dronedarone for maintenance of sinus rhythm in patients with atrial fibrillation or atrial flutter has comp…
-
FDA approval · 2010-02-05FDA Approved: LANOXIN — Supplemental Application (Covis Pharma US, Inc)
FDA approved a supplemental application for Lanoxin (digoxin) from Covis Pharma US, Inc., resulting in updates to the product labeling under…
-
FDA approval · 2010-02-04FDA Approved: AMIODARONE HYDROCHLORIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for amiodarone hydrochloride from Sun Pharmaceutical Industries, approving the supplemental filing f…
-
CLINICAL_TRIALS trial_result · 2010-02-04Clinical Trial Update: Isthmus Ablation With Gold Electrode for Treatment of Atrial Flutter (AURUM 8) [Phase 4]
Phase 4 clinical trial evaluating isthmus ablation with a gold electrode for atrial flutter has completed and results were posted in 2010.
-
CLINICAL_TRIALS research · 2010-02-02Clinical Trial Update: Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation [Phase 2, Phase 3]
This document provides an update on a Phase 2/3 trial comparing ATI-5923, a novel vitamin K antagonist, with warfarin for patients requiring…
-
EMA withdrawal · 2009-12-31EMA Withdrawn: Tikosyn (dofetilide) — Pfizer Limited
Tikosyn (dofetilide) has been withdrawn in the EU by Pfizer Limited, with the medicinal product no longer authorized for use.
-
CLINICAL_TRIALS trial_result · 2009-12-23Clinical Trial Update: A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation [Phase 3]
Phase 3 results for dronedarone (Multaq) in preventing hospitalization or death in patients with atrial fibrillation or atrial flutter were …